Shares of CEPHEID (CPHD) Sees Large Outflow of Money

CEPHEID (CPHD) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (2.52 million) in CEPHEID (CPHD). On Thursday, The value of composite uptick trades was $1.85 million, whereas, the value of composite downtick trades was $4.38 million and the ratio between the two was 0.42, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $2.05 million. The negative money flow of ($2.05 million) shows selling on strength. CEPHEID (CPHD) gained $0.06 intraday at $31.61 and registrered 0.19% for the week.


CEPHEID (CPHD) : The consensus price target for CEPHEID (CPHD) is $37.71 for the short term with a standard deviation of $5.43. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $47, however, the pessimist price target for the company is $28. The stock has recorded a 20-day Moving Average of 5.88% and the 50-Day Moving Average is 9.22%.

CEPHEID (NASDAQ:CPHD): The stock opened at $31.77 on Thursday but the bulls could not build on the opening and the stock topped out at $32.12 for the day. The stock traded down to $31.27 during the day, due to lack of any buying support eventually closed down at $31.37 with a loss of -0.57% for the day. The stock had closed at $31.55 on the previous day. The total traded volume was 768,475 shares.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.